drugset / Trial / NCT01247285

90 mg Fluoxetine Hydrochloride Capsules Under Non-Fasting Conditions

NCT01247285

Phase 1 Completed 26 enrolled Teva Pharmaceuticals USA
RandomizedCrossoverOpen-label

Summary

This study compared the relative bioavailability (rate and extent of absorption) of 90 mg Fluoxetine Hydrochloride Capsules by Teva Pharmaceuticals, USA with that of 90 mg PROZAC WEEKLY® Capsules by Eli Lilly and Company following a single oral dose (1 x 90 mg) in healthy adult volunteers under non-fasting conditions.

Timeline

Start
2001-05
Primary completion
2001-07
Completion
2001-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluoxetine Small molecule 90 mg Oral

Indications

No indication recorded.